StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences non-GAAP SG&A expenses as % of total revenues (%) (%)

Form 8-K Non-GAAP Financial Information

QuarterlyAnnual
Latest, Q2 2026
24.6%
Period ended Jun 30, 2026
Change on a year earlier
+5.3 pts
19.3% in Q2 2025
History
25 quarters
Since Q2 2020
Sources
21
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP SG&A expenses as % of total revenues (%) (%)Year on yearSource
Q2 2026Jun 30, 202624.6%+5.3 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202620.9%+2.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 202522.6%-2.6 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 202517.5%-1.5 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202519.3%-0.5 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202518.9%-1.7 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 202425.2%+2.6 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 202419.0%+0.4 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202419.8%-8.2 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 202420.6%-0.2 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202322.6%-4.7 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 202318.6%+1.4 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 202328.0%+6.3 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 202320.8%+4.4 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202227.3%+4.5 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 202217.2%+1.2 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP SG&A expenses as % of total revenues (%) (%), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng_sga_pct_rev

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.